SUMMARY A retrospective study of 245 fellow eyes of patients admitted in primary acute angleclosure glaucoma (ACG) is presented. Twenty-five (10-2%) had acute ACG in the fellow eye on presentation. Of the remaining 220, 33 (15%) subsequently developed acute ACG before prophylactic surgery was performed. Possible predisposing factors were analysed. The main findings were that acute ACG in the fellow eye occurred most frequently in hospital, or during the first month after discharge if prophylactic surgery was not performed. The instillation of mydriatics in the operated eye increased the risk to the fellow eye. Pilocarpine and carbonic anhydrase inhibitors confer the best protection on the fellow eye, but no medical regimen entirely prevented an attack of acute ACG in the fellow eye.
The aim of this retrospective study was to determine the behaviour of the fellow eye in patients admitted with primary acute angle-closure glaucoma (ACG). The possible factors which might precipitate acute ACG in this eye have been studied.
The consequences of an attack of acute ACG are well documented. They include peripheral field loss from ischaemic damage to the optic nerve head,' some loss of visual acuity2 even if the attack is treated at its inception,3 and a lowering of endothelial cell density in attacks which last 3 days or more.4 It is therefore advisable to prevent an attack of acute ACG in the fellow eye whenever possible.
Patients and methods
Two hundred and forty-five patients admitted as emergencies to the Birmingham and Midland Eye Hospital in primary acute ACG during the period of January 1972 to December 1978 were studied. Patients with chronic angle closure were excluded, and all the fellow eyes had narrow angles. One hundred and seventy (69%) were female and 75 (31%) male, their mean age being 66-8 years.
The incidence and timing of acute ACG attacks in the fellow eye were studied and the risk to the fellow eye during the periods outlined in Table 1 The following factors were investigated: the general health and systemic medication of all patients at presentation; the topical and systemic medication prescribed pre-and postoperatively, on discharge, and during the follow-up period.
Although individual treatment regimens varied greatly, it was possible to group them according to the strength and frequency of pilocarpine instillation in the fellow eye and according to whether or not a mydriatic was instilled in the operated eye. Mydriatics to the operated eye included atropine 1%, Mydrilate (cyclopentolate HCI) 1%, phenylephrine 10%, and homatropine 2% instilled one to 3 times a day. Comparisons were made in each case between patients whose fellow eye developed acute ACG and patients whose fellow eye escaped acute ACG.
Results
Incidence of attacks. Fifty-eight patients (23.6%) developed an attack of acute ACG in the fellow eye Table -2 . Twenty-five patients (10-2%) had bilateral acute ACG on admission, and 7 of these were induced by a mydriatic. Of the remaining 220 patients 9 developed acute ACG in the fellow eye prior to surgery on the first eye, and 14 more developed similar attacks in the early postoperative period. The greatest susceptibility to acute ACG in the fellow eye is from the time of admission up to the first month after discharge, the first postoperative week being the most critical period. This increased susceptibility is illustrated by the high number of attacks per 100 eyes per day (attack rate) during this period. In relation to postoperative medication, the results in Table 4 show a much higher incidence of acute ACG in the fellow eye when mydriatics had been prescribed for the operated eye and no prophylaxis for the fellow eye. Conversely no acute ACG occurred in fellow eyes if mydriatics were not used on the operated eve.
First month offollow-up (Table 5 ). Seven out of 52 fellow eves developed acute ACG during this period, and these were confined to the 38 patients receiving mydriatic in the operated eye. None of the 14 patients receiving no mydriatic to the operated eye developed acute ACG (all patients were on pilocarpine to the fellow eye).
Subsequent follow-up. Once unoperated eyes had been followed up for more than one month, and mydriatic drops to the operated eye had been stopped, the liability to an acute ACG attack became less (Table 1) . Nonetheless, attacks did occur up to 4 years after initial admission.
Discussion
The sample of patients studied is representative of patients presenting with acute ACG. The 2:1 female preponderance and the mean age in the mid 60s is consistent with the many previous studies of this condition. The findings of this study confirm Lowe's observation5 that no medical regimen guarantees freedom from an attack of acute ACG in the fellow eye.
INCIDENCE AND TIMING OF FELLOW EYE ATTACKS
Acute ACG in the fellow eye occurs most frequently during the period between the initial onset of symptoms in the acute eye and the end of the first month of out patient follow up. As regards the timing of this procedure, the results of this study would favour bilateral simultaneous surgery on the acute and the fellow eye as the only means of avoiding acute ACG occurring in the fellow eye postoperatively. The principal arguments against Behaviour of the fellow eye in acute angle-closure glaucoma this would be the risk of endophthalmitis or malignant glaucoma occurring bilaterally. However, none of the 51 patients submitted to simultaneous bilateral surgery had either of these complications; nor did they occur in any of the patients treated surgically on separate occasions. However, in view of the possible disastrous consequences of malignant glaucoma or endophthalmitis occurring bilaterally, however infrequently, some surgeons would still prefer not to perform bilateral simultaneous surgery on the acute and the fellow eye, and surgery on the fellow eye is occasionally postponed for various reasons. Therefore the question remains how best to treat the fellow eye until this is performed. Carbonic anhydrase inhibitors do appear to have a weak protective effect, and this would be consistent with their established place in the initial treatment of acute ACG.
Pilocarpine appears to have a protective effect when compared with no prophylactic treatment, especially if a mydriatic is used in the operated eye. Aqueous pilocarpine is effective only for 6 hours whatever its strength, so a frequency of instillation of 4 times a day would be logical. However, no individual pilocarpine regimen conferred a significantly greater protective effect in this series. An increased risk to the fellow eye is caused by the instillation of mydriatic in the operated eye. This was true whether the patient was in hospital or at home. It is unlikely that enough topically applied mydriatic is absorbed systemically to cause an attack of acute ACG in the fellow eye, and it is more likely that mydriatic is either mistakenly applied to the fellow eye or is inadvertently transferred to the fellow eye by rubbing both eyes in turn. The acute eye often requires mydriatic treatment postoperatively, and, as this puts the fellow eye at risk from acute ACG, surgery to that eye should be performed as soon as possible. If the patient has to go home prior to prophylactic surgery, mydriatics in the operated eye should be avoided where possible.
CONCLUSIONS
Acute primary ACG is potentially a bilateral condition with early involvement of the second eye being frequent. In these patients the fellow eye will be at risk from a similar attack no matter what medical treatment is given. There is a high incidence of acute ACG in the fellow eye when the patient is in hospital, and the risk is further increased by mydriatic treatment to the operated eye, particularly if the fellow eye is not protected by pilocarpine. Prophylactic peripheral iridectomy on the fellow eye should be done either simultaneously or within a few days of surgery on the acute eye, and it is not advisable to send the patient home or postpone surgery longer than is absolutely necessary. During the interval before surgery to the fellow eye pilocarpine drops instilled 6 hourly appear to be the safest treatment, and supplementary acetazolamide 250 mg 2 to 4 times a day may possibly confer additional protection.
